Skip to main content

Chesapeake Energy Stock Looks Like a Dead Cat Bounce

Chesapeake Energy Stock Looks Like a Dead Cat BounceShares of Chesapeake Energy stock (NYSE:CHK) are struggling to maintain tepid gains. The CHK stock price has been climbing modestly since Dec.18 on the announcement of a life preserver deal. The company refinanced some of its debt in an effort to stop the clock on its slide towards insolvency. One of the key components of the deal was the five-year timeline to pay back the debt. As Will Healy writes, this is giving the company a precious commodity, time.Source: Casimiro PT / Shutterstock.com However, there is a harsh calculus to investing in CHK stock, even as a speculative play. There is a very reasonable chance that the company will not be able to pay back the debt. This isn't because the company is poorly managed. It's actually worse than that. The company's business model no longer works. And that's why any idea of a comeback looks like nothing more than a dead cat bounce. The Risk and Reward of Being First Through the DoorAt one time, Chesapeake was the second-largest producer of natural gas. And when the fracking boom happened at the beginning of this decade, CHK was in the lead. But when you're first through the door, you become a target. And that's where the news got bad for Chesapeake.InvestorPlace - Stock Market News, Stock Advice & Trading TipsDrilling for shale via fracking became an easy target for environmental lobbyists. And not without reason. However, when you're a one-trick pony and that trick is no longer profitable, you have to find another way to be profitable. For Chesapeake, the company tried to become a "traditional" oil company. But the debt still remained and CHK stock started its slow and steady decline. * 10 Best Stocks to Beat the Market in 2020 And the real problem for CHK is that the debt, which is now nearly $10 billion is still there. And when you're a company with a $1.86 billion market cap, $10 billion is an alarming amount of debt. Chesapeake Can't Run Out the ClockIn a recent article, my InvestorPlace colleague Josh Enomoto used a football analogy that I'll take in a slightly different direction. Right now, Chesapeake is doing the prudent things it needs to do to extend the game. But that doesn't mean the odds of winning the game get any better. It just means the company is buying time. And most investors, like fans, are heading for the exits.I suppose you could look at the stock just about crossing over its 50-day moving average. You could probably justify a short-term trade with a relative strength indicator of around 60. But CHK stock has been a purely speculative play for a long time and it looks to be more of the same. What's Next for CHK Stock?In the case of CHK stock, no news would really be good news. That's because right now, all the news is bad and getting worse. There is more production coming from the Middle East. Royal Dutch Shell (NYSE:RDS) announced it was taking a major write down. This came on the heels of Chevron (NYSE:CVX) announcing its own write down.And more major oil companies are expected to follow suit. Now, Goldman Sachs (NYSE:GS) is announcing that it will no longer be financing coal projects, or oil and gas exploration in the Arctic.All of these are near-term headwinds for Chesapeake Energy stock. And that doesn't take into account that we are approaching an election year.The stark reality for Chesapeake Energy is that they are dealing with too many factors that are completely out of its control. 20 years ago, the company's venture into shale and fracking looked to be the wave of the future. But sometimes, like laser discs, an idea just becomes outdated. In the case of CHK, the opportunities for shale and fracking are just obsolete.As of this writing, Chesapeake stock was down over 60% for the year. The volatile oil and gas industry as a whole is down about 18%. There are other speculative plays in this sector. It seems investors would be better off finding those.As of this writing, Chris Markoch had no position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 2019 Losers That Will Be 2020 Winners * 7 Safe Dividend Stocks for Investors to Buy Right Now * 5 Artificial Intelligence Stocks to Consider The post Chesapeake Energy Stock Looks Like a Dead Cat Bounce appeared first on InvestorPlace.




from Yahoo Finance https://ift.tt/37gVm7L

Comments

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be